I'm sorry, I could have used other words. I just don't understand why somebody with a repuation would write such an article, about such a speculative stock. Even if it is a good investment, to many it will appear to be not well intended (or perhaps it's just me).
Someone posted this in response to the article.
Someone posted this in response to the article.
Today, Vringo announced that they they will be selling 2.7M shares of the stock via this SEC filing: http://www.sec.gov/Archives/edgar/data/1410428/000114420412018984/v307921_s3.htm. This is a secondary filing, meaning all proceeds will go directly to shareholders.
It appears the same happened almost exactly 2 years ago with the same largest shareholder selling secondary shares immediately after Altucher's article. The company was Star Scientific (CIGX), with Altucher's article here (http://seekingalpha.com/article/197650-did-star-scientific-just-find-a-cure-for-alzheimer-s-disease) and the secondary filing happened just a couple of weeks later with this S3 prospectus (http://google.brand.edgar-online.co...mpanyid=5213&ppu=%2fdefault.aspx%3fsym%3dCIGX). His claim was that the stock would go to $15-20, but it is still around the same range of $3 as it was two years ago.
The same shareholder in the 2 companies selling secondary shares is Iroquois Master Fund Ltd, in the case of Vringo representing the largest sale of shares and in the case of CIGX the second largest sale of shares.
It is true that it would make sense for shareholders of both companies to de-risk by selling some shares after getting a bump in the stock price, but doesn't this seem more than coincidental?
